HIA
PTGX icon

Harbor Investment Advisory’s Protagonist Therapeutics PTGX Stock Holding History

Harbor Investment Advisory’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$91.4K Sell
649
-75
-10% -$10.7K 0.01% 585
2026
Q2 		$88.7K Buy
+724
New +$75.6K 0.01% 592

Other funds holding PTGX

FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Harbor Investment Advisory's PTGX Position: Q3 2026 in Review

Harbor Investment Advisory reduced its Protagonist Therapeutics (PTGX) stake by 10% in Q3 2026, selling an estimated $10.7K and leaving 649 shares worth $91.4K. The position accounts for 0.01% of the portfolio, ranked #585.

Harbor Investment Advisory first reported a position in PTGX in Q2 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Harbor Investment Advisory held 649 shares of Protagonist Therapeutics worth $91.4K as of Q3 2026.
  • Harbor Investment Advisory sold 75 Protagonist Therapeutics shares in Q3 2026, an estimated $10.7K.
  • Protagonist Therapeutics made up 0.01% of Harbor Investment Advisory's portfolio in Q3 2026, its #585 holding.
  • Harbor Investment Advisory first reported a position in Protagonist Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Harbor Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.